[Pharmacodynamics of alizapride (author's transl)].
Studies of alizapride (N[(allyl-1 pyrrolidinyl-2) methyl] méthoxy-2 azimido-4,5 benzamide hydrochlorate) in mice and rats demonstrated little toxicity, particularly after parenteral administration. Alizapride's main pharmacodynamic effects are on the central nervous system. It is very effective against emesis induced by apomorphine and dihydrogenated ergot alkaloids in dogs. In this respect it is three times more effective than metoclopramide. In contrast to neuroleptics, alizapride does not modify equilibrium reflexes in mice, nor does it reinforce hypnosis induced by barbiturates. Only minor central antidopaminergic effects were recorded, less marked than those seen with metoclopramide. In mice, alizapride has no anticonvulsant or analgesic effects. It has little action on the autonomic nervous system or on the cardiovascular system. Alizapride has no antihistaminic or parasympatholytic effect. In dogs, sympatholytic effects and hypotension are seen only after giving a much higher dose than that which is effective against apomorphine and dihydrogenated ergot alkaloids.
D000818:Animals; D000932:Antiemetics / Q000494:pharmacology*; D001058:Apomorphine / Q000037:antagonists & inhibitors; D001522:Behavior, Animal / Q000187:drug effects; D002490:Central Nervous System / Q000187:drug effects*; D004285:Dogs; D004877:Ergoloid Mesylates / Q000037:antagonists & inhibitors; D006168:Guinea Pigs; D008297:Male; D008787:Metoclopramide / Q000494:pharmacology; D051379:Mice; D008815:Mice, Inbred Strains; D011759:Pyrrolidines / Q000494:pharmacology* / Q000633:toxicity; D011817:Rabbits; D051381:Rats; D011919:Rats, Inbred Strains
D000932:Antiemetics; D011759:Pyrrolidines; D004877:Ergoloid Mesylates; D008787:Metoclopramide; D001058:Apomorphine; C033968:alizapride
Etude pharmacodynamique de l'alizapride.